Get the app
US › Healthcare

Skye Bioscience, Inc. Common Stock (SKYE)

US · Healthcare · Biotechnology

$0.99-4.78%
Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-10.8M
EPS
$-0.27
EPS estimate
$-0.29

EPS came in at -0.27 against a street estimate of -0.29 — a beat of 6.9%.

Key statistics

Market cap
$4.6M
Forward P/E
0.0
P/B
1.96
Book value
$-0.11
EPS (TTM)
$-10.16
52-week high
$2.25
52-week low
$0.26
50-day MA
$1.68
200-day MA
$4.76
Beta
3.15

Analyst view

Analysts rate Skye Bioscience, Inc. Common Stock a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $68.00.

Shareholding

Insiders
4.24%
Institutions
46.12%

Largest institutional holders

FundStake
Versant Venture Management LLC45.34%
Baker Bros Advisors LP35.58%
Vanguard Capital Management, LLC17.25%
Sphera Funds Management Ltd.15.33%
BlackRock Inc5.26%
Geode Capital Management, LLC4.92%
Millennium Management LLC4.48%
Vanguard Fiduciary Trust Co2.35%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Skye Bioscience, Inc. Common Stock — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncMerck & Company IncUnitedHealth Group IncorporatedNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-11-07.